Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Diagnostics company updates NMP66 protein program for breast cancer detection
June 23rd, 2005
Matritech (MZT), a developer of protein-based diagnostic products for the early detection of cancer, provided an update on preliminary results of pre-clinical tests in its NMP66 program for breast cancer detection. Researchers analyzed 298 prospectively collected, blinded serum samples, using experimental versions of a colorimetric sandwich immunoassay and qualitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect the NMP66 protein complex in the blood of women with breast cancer. Serum samples were from women with a range of stages of breast cancer, biopsy confirmed benign breast diseases, and those with no mammographic evidence of breast...
Source: Women's Health Weekly (2005-06-23)
|
